Costantino Del Giudice1, Alexandre Galloula2, Clarisse Tiercelin3, Aurélie Vilfaillot4, Jean Marc Alsac5,6, Emmanuel Messas2,6, Carole L Déan7, Etienne Larger3, Marc Sapoval6,7. 1. Department of Radiology, Interventional Radiology, Institut Mutualiste Montsouris, 42 Boulevard Jourdan, 75014, Paris, France. costantino.delgiudice@imm.fr. 2. Department of Vascular Medicine, Hôpital Européen George Pompidou, Assistance Publique Hôpitaux de Paris, 75015, Paris, France. 3. Diabetology, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, 75015, Paris, France. 4. Clinical Investigation Unit, Hôpital Européen George Pompidou, Assistance Publique Hôpitaux de Paris, 75015, Paris, France. 5. Vascular Surgery, Hôpital Européen George Pompidou, Assistance Publique Hôpitaux de Paris, 75015, Paris, France. 6. Université de Paris, INSERM U970, 75015, Paris, France. 7. Vascular and Oncological Interventional Radiology, Hôpital Européen George Pompidou, Assistance Publique Hôpitaux de Paris, 75015, Paris, France.
Abstract
PURPOSE: Restenosis remains a limitation of endovascular angioplasty with a patency of 30% in BTK at 12 months. Several studies on drug-coated balloons have not demonstrated any improvements in terms of patency and target lesions revascularization in BTK lesions. This prospective single-centre cohort study evaluates the safety and efficacy of a new generation low-dose drug-coated balloon (DCB) with a reduced crystalline structure to treat below the knee (BTK) lesions in patients with critical limb ischemia (CLI). MATERIALS AND METHODS: Between November 2016 and November 2017, 30 consecutive patients (mean 68.8 ± 12.7 years, 6 female) with BTK lesions and CLI were included in this single-centre, prospective non-randomized cohort study. All patients with rest pain and/or ischemic wound associated with BTK lesions were included in the study. Mean lesion length was 133.6 ± 94.5 mm and 18(60%) were chronic total occlusions. The primary safety outcome parameter was a composite of all-cause mortality and major amputation at 6 months. The primary efficacy outcome parameter was the primary angiographic patency at 6 months (defined as freedom from clinically driven target lesion revascularization and the absence of significant restenosis (> 50%) as determined by core laboratory angiography assessment. Immediate technical success, late lumen loss (LLL), clinical target lesion revascularization (TLR) and ulcer healing rates at 12 months were also evaluated. RESULTS: Immediate technical success was 97%(29/30): one patient had an acute thrombosis at the completion of index procedure. Primary safety outcome parameter was 94%(28/30): one patient underwent major amputation and one patient died of other comorbidities at 2 months. Another patient had a major amputation at 7.5 months. Angiographic follow-up was available in 20 patients. Primary angiographic patency was 57%(12/21 lesions), and LLL was 0.99 ± 0.68 mm at 6 months. Freedom from TLR was 89% at 12 months. The rate of ulcer healing was 76% at 12 months. CONCLUSION: Ranger DCB balloons to treat CLI patients demonstrated a positive trend with good safety outcomes parameters. Further randomized studies are needed to understand the usefulness compared to POBA.
PURPOSE: Restenosis remains a limitation of endovascular angioplasty with a patency of 30% in BTK at 12 months. Several studies on drug-coated balloons have not demonstrated any improvements in terms of patency and target lesions revascularization in BTK lesions. This prospective single-centre cohort study evaluates the safety and efficacy of a new generation low-dose drug-coated balloon (DCB) with a reduced crystalline structure to treat below the knee (BTK) lesions in patients with critical limb ischemia (CLI). MATERIALS AND METHODS: Between November 2016 and November 2017, 30 consecutive patients (mean 68.8 ± 12.7 years, 6 female) with BTK lesions and CLI were included in this single-centre, prospective non-randomized cohort study. All patients with rest pain and/or ischemic wound associated with BTK lesions were included in the study. Mean lesion length was 133.6 ± 94.5 mm and 18(60%) were chronic total occlusions. The primary safety outcome parameter was a composite of all-cause mortality and major amputation at 6 months. The primary efficacy outcome parameter was the primary angiographic patency at 6 months (defined as freedom from clinically driven target lesion revascularization and the absence of significant restenosis (> 50%) as determined by core laboratory angiography assessment. Immediate technical success, late lumen loss (LLL), clinical target lesion revascularization (TLR) and ulcer healing rates at 12 months were also evaluated. RESULTS: Immediate technical success was 97%(29/30): one patient had an acute thrombosis at the completion of index procedure. Primary safety outcome parameter was 94%(28/30): one patient underwent major amputation and one patient died of other comorbidities at 2 months. Another patient had a major amputation at 7.5 months. Angiographic follow-up was available in 20 patients. Primary angiographic patency was 57%(12/21 lesions), and LLL was 0.99 ± 0.68 mm at 6 months. Freedom from TLR was 89% at 12 months. The rate of ulcer healing was 76% at 12 months. CONCLUSION: Ranger DCB balloons to treat CLI patients demonstrated a positive trend with good safety outcomes parameters. Further randomized studies are needed to understand the usefulness compared to POBA.
Entities:
Keywords:
Below the knee; Critical limb ischemia; Drug eluting ballons
Authors: D J Adam; J D Beard; T Cleveland; J Bell; A W Bradbury; J F Forbes; F G R Fowkes; I Gillepsie; C V Ruckley; G Raab; H Storkey Journal: Lancet Date: 2005-12-03 Impact factor: 79.321
Authors: L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes; R B Rutherford Journal: Int Angiol Date: 2007-06 Impact factor: 2.789
Authors: Marie D Gerhard-Herman; Heather L Gornik; Coletta Barrett; Neal R Barshes; Matthew A Corriere; Douglas E Drachman; Lee A Fleisher; Francis Gerry R Fowkes; Naomi M Hamburg; Scott Kinlay; Robert Lookstein; Sanjay Misra; Leila Mureebe; Jeffrey W Olin; Rajan A G Patel; Judith G Regensteiner; Andres Schanzer; Mehdi H Shishehbor; Kerry J Stewart; Diane Treat-Jacobson; M Eileen Walsh Journal: Circulation Date: 2016-11-13 Impact factor: 29.690
Authors: S D Patel; L Biasi; I Paraskevopoulos; J Silickas; T Lea; A Diamantopoulos; K Katsanos; H Zayed Journal: Br J Surg Date: 2016-09-21 Impact factor: 6.939
Authors: Abd Moain Abu Dabrh; Mark W Steffen; Chaitanya Undavalli; Noor Asi; Zhen Wang; Mohamed B Elamin; Michael S Conte; Mohammad Hassan Murad Journal: J Vasc Surg Date: 2015-09-26 Impact factor: 4.268
Authors: O Iida; Y Soga; D Kawasaki; K Hirano; T Yamaoka; K Suzuki; Y Miyashita; H Yokoi; M Takahara; M Uematsu Journal: Eur J Vasc Endovasc Surg Date: 2012-08-28 Impact factor: 7.069
Authors: Katja B C Schamp; Robbert Meerwaldt; Michel M P J Reijnen; Robert H Geelkerken; Clark J Zeebregts Journal: Ann Vasc Surg Date: 2012-07-25 Impact factor: 1.466